Cholangiocarcinoma (bile duct cancer)
Board exam relevance: in 1 of more than 100 exam reports · rank 181- Synonyms
- bile duct cancer, CCA, Klatskin tumor, intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, extrahepatic cholangiocarcinoma
- Specialty
- Internal medicine · Gastroenterology
- Images
- CT 1 · Histology 1 · Gross specimen 1
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Images (3)
CT
Histology
Gross specimenDefinition
Cholangiocarcinoma (CCA, bile duct cancer) comprises a heterogeneous group of malignancies arising in the biliary tree. Histologically, they are adenocarcinomas or mucinous carcinomas with tubular and/or papillary structures and a variable fibrous stroma. CCA is the second most common primary liver malignancy after hepatocellular carcinoma; it accounts for about 15% of primary liver tumors and 3% of gastrointestinal cancers.
Classification
By location:
- intrahepatic (iCCA): above the second-order bile ducts, in the liver periphery
- perihilar (pCCA): in the right and/or left hepatic duct or at their junction (Klatskin tumor)
- distal (dCCA): in the common bile duct; the boundary between perihilar and distal is the insertion of the cystic duct
Perihilar and distal tumors are collectively called extrahepatic CCA; they are considerably more common than intrahepatic tumors, with perihilar tumors forming the largest group.
By growth pattern: mass-forming (mass in the liver parenchyma), periductal-infiltrating (spreading within and along the duct wall) and intraductal-growing (polypoid or papillary into the duct lumen).
Staging: according to the AJCC TNM system.
Occurrence & epidemiology
Cholangiocarcinomas are rare (worldwide incidence about 0.3–6 per 100,000 population per year) but considerably more common in regions with liver flukes such as South Korea, China and Thailand; incidence and death rates have increased worldwide over recent decades. In Germany, about 4,670 malignant tumors of the gallbladder and extrahepatic bile ducts were diagnosed in 2023, about 72% of them in the bile ducts; the risk increases continuously with age.
Aetiopathogenesis
The exact triggers are not clearly identified; the main risk factor is age. Established or possible risk factors:
- primary sclerosing cholangitis and other chronic inflammatory bile duct diseases
- liver flukes (especially in Asia)
- choledochal cysts, congenital biliary anomalies (Caroli syndrome), intrahepatic bile duct stones
- liver cirrhosis, viral hepatitis B and C, alcohol-related liver disease
- severe obesity, diabetes mellitus, smoking
- inflammatory bowel disease
At the molecular level, numerous alterations are found, including in TP53, KRAS, BAP1 and ARID1A, as well as IDH1/IDH2 mutations and FGFR2 fusions in intrahepatic CCA.
Clinical features
Cholangiocarcinomas are usually asymptomatic in early stages and are therefore often diagnosed late.
- perihilar and distal CCA: the most frequent symptom is jaundice due to biliary obstruction; most patients have painless obstructive jaundice with pruritus, along with pale stools; early perihilar tumors sometimes cause only vague abdominal pain, loss of appetite and loss of body weight
- intrahepatic CCA: jaundice less frequent and mostly only in advanced disease; an incidental finding in about 20–25%
- other signs: fatigue, palpable mass, hepatomegaly, palpable gallbladder in distal CCA (Courvoisier sign)
- pain resembling biliary colic or constant and progressive; rarely sepsis due to acute cholangitis
Diagnosis
- Suspicion with unexplained extrahepatic biliary obstruction, especially in primary sclerosing cholangitis or ulcerative colitis
- Laboratory tests: results reflect the degree of cholestasis; CEA and CA 19-9 as tumor markers
- Ultrasound (endoscopic if appropriate) as initial imaging, followed by MRCP or CT cholangiography
- CT: the standard method for assessing the primary tumor, adjacent structures and thoracic and abdominal spread; MRI similarly accurate, with diffusion-weighted imaging and MRCP, particularly important in perihilar CCA. Intrahepatic CCA typically shows arterial peripheral rim enhancement with progressive contrast uptake into the delayed phase
- Tissue diagnosis: there is no specific radiological pattern; tissue is obtained by brush cytology during endoscopic ductography, ultrasound- or CT-guided biopsy or fine-needle aspiration
Cholangiocarcinoma in PSC
- In primary sclerosing cholangitis, the CCA risk is markedly increased (about 161-fold in a Swedish cohort); the cumulative 10-year risk is about 8%
- Workup of a dominant stricture: MRI with MRCP and endoscopic duct imaging with brush cytology or forceps biopsy; FISH analysis can increase the diagnostic yield of brush cytology
Treatment principles
- The only curative option is complete surgical resection followed by adjuvant chemotherapy; in selected cases of perihilar cancer, liver transplantation may be considered in specialist centres.
- Cholestasis is drained endoscopically or percutaneously, and treatment is planned in a multidisciplinary tumour board.
- In advanced disease, systemic therapy combining chemotherapy and an immune checkpoint inhibitor is used; molecular testing allows targeted therapies when suitable alterations are found.
Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.
Keep learning in the app
Further reading (open access)
Cross-references
More topics: Gastroenterology
- Ulcerative colitis
- Gastritis (type A, B and C)
- Peptic ulcer disease
- Crohn's disease
- Choledocholithiasis and acute cholangitis
- Gallstones and acute cholecystitis
- Chronic pancreatitis
- Clostridioides difficile infection
- Diverticular disease and diverticulitis
- Eosinophilic esophagitis
- Familial adenomatous polyposis (FAP)
- Gastro-esophageal reflux disease (GERD)
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.
Related pages: Ulcerative colitis · Gastritis (type A, B and C) · Peptic ulcer disease
Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.